Indeed, preclinical studies and recent clinical trials with hepcidin mimetics indicate that enhancing the hepcidin activity in patients with polycythemia vera is effective in controlling erythrocytosis [48,49]. The gene discussed is HAMP; the disease is acquired polycythemia vera.